Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Entera Bio (ENTX) Enterprise Value (2018 - 2026)

Entera Bio has reported Enterprise Value over the past 9 years, most recently at -$14.9 million for Q4 2025.

  • For the quarter ending Q4 2025, Enterprise Value fell 71.86% year-over-year to -$14.9 million, compared with a TTM value of -$14.9 million through Dec 2025, down 71.86%, and an annual FY2025 reading of -$14.9 million, down 71.86% over the prior year.
  • Enterprise Value came in at -$14.9 million for Q4 2025, down from -$8.6 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$6.9 million in Q3 2024 to a low of -$27.4 million in Q3 2021.
  • Median Enterprise Value over the past 5 years was -$11.7 million (2022), compared with a mean of -$13.9 million.
  • The sharpest move saw Enterprise Value tumbled 287.59% in 2021, then surged 50.55% in 2022.
  • Over 5 years, Enterprise Value stood at -$24.9 million in 2021, then skyrocketed by 50.55% to -$12.3 million in 2022, then grew by 10.48% to -$11.0 million in 2023, then increased by 21.41% to -$8.7 million in 2024, then plummeted by 71.86% to -$14.9 million in 2025.
  • Per Business Quant, the three most recent readings for ENTX's Enterprise Value are -$14.9 million (Q4 2025), -$8.6 million (Q3 2025), and -$10.9 million (Q2 2025).